Evidence map›Paper›PMID 36351775›Full record

ArticleChemMedChem2022

Prodrugs of the Archetypal Dynamin Inhibitor Bis-T-22.

Luke R Odell, Mark J Robertson, Kelly A Young, Andrew B McGeachie, Annie Quan, Phillip J Robinson, Adam McCluskey

Abstract read
In one paragraph

Article in ChemMedChem, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Luke R OdellThe University of Newcastle, University Drive, Callaghan, NSW 2308, Australia.ORCID 0000-0001-7658-5103
Mark J RobertsonThe University of Newcastle, University Drive, Callaghan, NSW 2308, Australia.ORCID 0000-0002-2140-2717
Kelly A YoungThe University of Newcastle, University Drive, Callaghan, NSW 2308, Australia.ORCID 0000-0002-7252-4693
Andrew B McGeachieCell Signalling Unit, Children's Medical Research Institute, The University of Sydney, 214 Hawkesbury Road, Westmead, NSW 2145, Australia.ORCID 0000-0003-2259-1465
Annie QuanCell Signalling Unit, Children's Medical Research Institute, The University of Sydney, 214 Hawkesbury Road, Westmead, NSW 2145, Australia.
Phillip J RobinsonCell Signalling Unit, Children's Medical Research Institute, The University of Sydney, 214 Hawkesbury Road, Westmead, NSW 2145, Australia.ORCID 0000-0002-7878-0313
Adam McCluskeyThe University of Newcastle, University Drive, Callaghan, NSW 2308, Australia.ORCID 0000-0001-7125-863X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Bis-T series of compounds comprise some of the most potent inhibitors of dynamin GTPase activity yet reported, e. g., (2E,2'E)-N,N'-(propane-1,3-diyl)bis(2-cyano-3-(3,4-dihydroxyphenyl)acrylamide) (2), Bis-T-22. The catechol moieties are believed to limit cell permeability, rendering these compounds largely inactive in cells. To solve this problem, a prodrug strategy was envisaged and eight ester analogues were synthesised. The shortest and bulkiest esters (acetate and butyl/tert-butyl) were found to be insoluble under physiological conditions, whilst the remaining five were soluble and stable under these conditions. These five were analysed for plasma stability and half-lives ranged from ∼2.3 min (propionic ester 4), increasing with size and bulk, to greater than 24 hr (dimethyl carbamate 10). Similar profiles where observed with the rate of formation of Bis-T-22 with half-lives ranging from ∼25 mins (propionic ester 4). Propionic ester 4 was chosen to undergo further testing and was found to inhibit endocytosis in a dose-dependent manner with IC

Indexed as

ProdrugsDynaminsEndocytosisEstersDynaminsEstersProdrugsBis-T-22dynaminendocytosisprodrug

Identifiers

PMID36351775
PMCPMC10947042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.